Xerox Holdings Corp
Change company Symbol lookup
Select an option...
XRX Xerox Holdings Corp
BIDU Baidu Inc
CDRO Codere Online Luxembourg SA
AMZN Amazon.com Inc
LYFT Lyft Inc
RRX Regal Rexnord Corp
JKS JinkoSolar Holding Co Ltd
FSLR First Solar Inc
CCV Churchill Capital V Corp
RF-C Regions Financial Corp
Go

Information Technology : Technology Hardware, Storage & Peripherals | Small Cap Value
Company profile

Xerox Holdings Corporation is a workplace technology company, building and integrating software and hardware for enterprises. It has developed the copier, the Ethernet, the laser printer and more. The Company has capabilities in artificial intelligence (AI), augmented reality (AR) driven service experiences, robotic process automation (RPA), sensors and services for Internet of Things (IoT), three-dimensional (3D) printing and Clean Technologies (clean tech). Its segments include Workplace Solutions which is made up of two strategic product groups, Entry and Mid-Range, which share common technology, manufacturing and product platforms; Production Solutions are designed for customers in graphic communications, in-plant and production print environments with high-volume printing requirements; Xerox Services includes a continuum of solutions and services that helps its customers; and FITTLE is engaged in financing for direct channel customer purchases of Xerox equipment.

Price
Delayed
$16.28
Day's Change
-0.19 (-1.15%)
Bid
--
Ask
--
B/A Size
--
Day's High
16.36
Day's Low
16.17
Volume
(Light)

Today's volume of 107,041 shares is on pace to be much lighter than XRX's 10-day average volume of 1,170,252 shares.

107,041

Novavax says its COVID vaccine is now available in Israel for use in people aged 12 and older

8:18 am ET September 16, 2022 (MarketWatch)
Print

Novavax Inc. said Friday that Israel has granted an import and use permit for the company's COVID vaccine for use in people aged 12 and older. The vaccine is protein based, using a more traditional technology than the mRNA used in the vaccines developed by Pfizer Inc. and German partner BioNTech SE and Moderna Inc. . The vaccine has now received authorization for use in adults aged 18 and older from more than 40 markets, including the U.S. It has also won authorization from the World Health Organization. Separately, the company said it has also won emergency use authorization in Taiwan for adolescents aged 12 through 17. Novavax shares were down 1.7% premarket and have fallen 77% in the year to date, while the S&P 500 has fallen 18%.

-Ciara Linnane

	

(END) Dow Jones Newswires

September 16, 2022 08:18 ET (12:18 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.